Affinity DataIC50: 0.0700nMAssay Description:Displacement of [125I]nonpeptide ligand (compound 7) from purified human recombinant alphaV-beta3More data for this Ligand-Target Pair
Affinity DataIC50: 0.0800nMAssay Description:Displacement of [125I]nonpeptide ligand (compound 7) from purified human recombinant alphaV-beta3More data for this Ligand-Target Pair
Affinity DataIC50: 0.0800nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 0.100nMAssay Description:Displacement of [125I]echistatin from human recombinant alpha-v beta-3 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.100nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 0.140nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.160nMAssay Description:Inhibition of 2(S)-(4-125-iodo-benzenesulfonylamino)-3-4-[2-(5,6,7,8-tetrahydro- [1,8]naphthyridin-2-yl)-ethyl]-benzoylamino-propionic acid binding t...More data for this Ligand-Target Pair
Affinity DataIC50: 0.240nMAssay Description:Inhibition of 2(S)-(4-125-iodo-benzenesulfonylamino)-3-4-[2-(5,6,7,8-tetrahydro- [1,8]naphthyridin-2-yl)-ethyl]-benzoylamino-propionic acid binding t...More data for this Ligand-Target Pair
Affinity DataIC50: 0.240nMAssay Description:Inhibition of 2(S)-(4-125-iodo-benzenesulfonylamino)-3-4-[2-(5,6,7,8-tetrahydro- [1,8]naphthyridin-2-yl)-ethyl]-benzoylamino-propionic acid binding t...More data for this Ligand-Target Pair
Affinity DataIC50: 0.25nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 0.300nMAssay Description:Displacement of [125I]echistatin from human recombinant alpha-v beta-3 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.350nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 0.400nMAssay Description:Displacement of [125I]echistatin from human recombinant alpha-v beta-3 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.440nMAssay Description:Displacement of [125I]nonpeptide ligand (compound 7) from purified human recombinant alphaV-beta3More data for this Ligand-Target Pair
Affinity DataIC50: 0.530nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.550nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.620nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.650nMAssay Description:Inhibition of 2(S)-(4-125-iodo-benzenesulfonylamino)-3-4-[2-(5,6,7,8-tetrahydro- [1,8]naphthyridin-2-yl)-ethyl]-benzoylamino-propionic acid binding t...More data for this Ligand-Target Pair
Affinity DataIC50: 0.700nMAssay Description:Displacement of [125I]echistatin from human recombinant alpha-v beta-3 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 0.820nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 0.930nMAssay Description:Displacement of [125I]nonpeptide ligand (compound 7) from purified human recombinant alphaV-beta3More data for this Ligand-Target Pair
Affinity DataIC50: 1.40nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 1.80nMAssay Description:Displacement of [125I]echistatin from human recombinant alpha-v beta-3 receptorMore data for this Ligand-Target Pair
Affinity DataIC50: 3nMAssay Description:Inhibition of alphaV-beta3 integrin bindingMore data for this Ligand-Target Pair
Affinity DataIC50: 3.38nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 4nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.20nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 4.90nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 5.5nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 5.90nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 6.10nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 6.30nMAssay Description:Agonist activity at rat CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fors...More data for this Ligand-Target Pair
Affinity DataIC50: 7nMAssay Description:Antagonist activity at human recombinant NPS receptor expressed in CHOK1 cells assessed as inhibition of NPS-induced calcium mobilization by FLIPR as...More data for this Ligand-Target Pair
Affinity DataIC50: 7.30nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 7.30nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 7.90nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 10nMAssay Description:Antagonist activity at human recombinant NPS receptor expressed in CHOK1 cells assessed as inhibition of NPS-induced calcium mobilization by FLIPR as...More data for this Ligand-Target Pair
Affinity DataIC50: 10.7nMAssay Description:Displacement of [125I]nonpeptide ligand (compound 7) from purified human recombinant alphaV-beta3More data for this Ligand-Target Pair
Affinity DataIC50: 11nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 12nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 13nMAssay Description:Inhibition of glycoprotein IIb/III integrin mediated fibrinogen binding to activated plateletsMore data for this Ligand-Target Pair
Affinity DataIC50: 14nMAssay Description:Antagonist activity at human recombinant NPS receptor expressed in CHOK1 cells assessed as inhibition of NPS-induced calcium mobilization by FLIPR as...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 16nMAssay Description:Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as inhibition of forskolin-induced cAMP production treated 15 mins before fo...More data for this Ligand-Target Pair
Affinity DataIC50: 17nMAssay Description:Inhibition of glycoprotein IIb/III integrin mediated fibrinogen binding to activated plateletsMore data for this Ligand-Target Pair